Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | AKT1 | P31749 | 6/20 | 0.43 |
| ▸ | AKT2 | P31751 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1660696 | 0.86 | AKT1 (0.51) | RAB9ANPC1AKT1AKT2CGAS | |
| SCHEMBL1661550 | 0.81 | AKT1 (0.51) | RAB9ANPC1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL1659968 | 0.78 | CGAS (0.47) | RAB9ANPC1SMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL1659988 | 0.78 | ADORA2A (0.46) | RAB9ANPC1SMN1; SMN2AKT1AKT2 | |
| SCHEMBL1660006 | 0.77 | ADORA3 (0.49) | RAB9ANPC1AKT1AKT2ADORA3 | |
| SCHEMBL23473927 | 0.73 | ELANE (0.47) | ADORA3 | |
| SCHEMBL360566 | 0.70 | AKT2 (0.80) | AKT1AKT2 | |
| SCHEMBL1660062 | 0.69 | RAD51 (0.48) | RAB9ANPC1SMN1; SMN2CYP2C19ALDH1A1 | |
| SCHEMBL11812753 | 0.69 | MAPT (0.44) | RAB9ANPC1SMN1; SMN2CYP2C9ALDH1A1 | |
| SCHEMBL1659904 | 0.68 | KDM4E (0.47) | RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2314588-B1 | 4H-Pyrido[1,2-a]pyrimidin-4-one derivatives as modulators of the estrogen-related receptors | GUANGZHOU INST BIOMED & HEALTH (CN) | 2014-11-05 | — | — | EP | claimed |
| US-20150011544-A1 | COMPOUNDS OF ESTROGEN-RELATED RECEPTOR MODULATORS AND THE USES THEREOF | GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACADEMY OF SCIENCES (CN) | 2015-01-08 | — | — | US | disclosed |
| US-20150011544-A1 | COMPOUNDS OF ESTROGEN-RELATED RECEPTOR MODULATORS AND THE USES THEREOF | GUANGZHOU INST OF BIOMEDICINE & HEALTH CHINESE ACADEMY OF SCIENCES (CN) | 2015-01-08 | — | — | US | disclosed |
| EP-2314588-B1 | 4H-Pyrido[1,2-a]pyrimidin-4-one derivatives as modulators of the estrogen-related receptors | GUANGZHOU INST BIOMED & HEALTH (CN) | 2014-11-05 | — | — | EP | disclosed |
| EP-2314588-B1 | 4H-Pyrido[1,2-a]pyrimidin-4-one derivatives as modulators of the estrogen-related receptors | GUANGZHOU INST BIOMED & HEALTH (CN) | 2014-11-05 | — | — | EP | disclosed |
| US-8853221-B2 | Compounds of estrogen-related receptor modulators and the uses thereof | GUANGZHOU INSTITUTE OF BIOMEDICINE & HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-07 | — | — | US | disclosed |
| US-8853221-B2 | Compounds of estrogen-related receptor modulators and the uses thereof | GUANGZHOU INSTITUTE OF BIOMEDICINE & HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-07 | — | — | US | disclosed |
| US-8853221-B2 | Compounds of estrogen-related receptor modulators and the uses thereof | GUANGZHOU INSTITUTE OF BIOMEDICINE & HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2014-10-07 | — | — | US | disclosed |
| CN-101628913-B | Compounds useful as estrogen-related receptor modulators and uses thereof | GUANGZHOU INST BIOMED & HEALTH | 2013-01-23 | — | — | CN | disclosed |
| US-20110218196-A1 | COMPOUNDS OF ESTROGEN-RELATED RECEPTOR MODULATORS AND THE USES THEREOF | GUANGZHOU INSTITUTE OF BIOMEDICINE & HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218196-A1 | COMPOUNDS OF ESTROGEN-RELATED RECEPTOR MODULATORS AND THE USES THEREOF | GUANGZHOU INSTITUTE OF BIOMEDICINE & HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2011-09-08 | — | — | US | disclosed |
| US-20110218196-A1 | COMPOUNDS OF ESTROGEN-RELATED RECEPTOR MODULATORS AND THE USES THEREOF | GUANGZHOU INSTITUTE OF BIOMEDICINE & HEALTH, CHINESE ACADEMY OF SCIENCES (CN) | 2011-09-08 | — | — | US | disclosed |
| EP-2314588-A1 | COMPOUNDS OF ESTROGEN-RELATED RECEPTOR MODULATORS AND THE USES THEREOF | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences (CN) | 2011-04-27 | — | — | EP | disclosed |
| EP-2314588-A1 | COMPOUNDS OF ESTROGEN-RELATED RECEPTOR MODULATORS AND THE USES THEREOF | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences (CN) | 2011-04-27 | — | — | EP | disclosed |
| CN-101628913-A | Compounds useful as estrogen-related receptor modulators and uses thereof | GUANGZHOU INST BIOMED & HEALTH | 2010-01-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218196-A1 | COMPOUNDS OF ESTROGEN-RELATED RECEPTOR MODULATORS AND THE USES THEREOF | ESRRA, ESRRB, ESRRG | RAB9A 1490/4885NPC1 1501/4885SMN1; SMN2 4563/4885 |
| US-20150011544-A1 | COMPOUNDS OF ESTROGEN-RELATED RECEPTOR MODULATORS AND THE USES THEREOF | ESRRA, ESRRB, ESRRG | RAB9A 1490/4885NPC1 1501/4885SMN1; SMN2 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.